Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.

@article{Markova2009MonitoringOM,
  title={Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.},
  author={J. A. Markova and Zuzana Trnkov{\'a} and Petra Michkov{\'a} and Jacqueline Soukupov{\'a} Maaloufov{\'a} and Jan Star{\'y} and Petr Cetkovsk{\'y} and Jiř{\'i} Schwarz},
  journal={Leukemia & lymphoma},
  year={2009},
  volume={50 9},
  pages={1448-60}
}
Mutational analysis of C-KIT, fms-like tyrosine kinase 3 (FLT3), and JAK2 genes was performed in 60 patients with core binding factor acute myeloid leukemia (CBF-AML). Patients reaching molecular remission had lower incidence of relapse and better overall survival (OS) than those not achieving molecular remission (p = 0.008 and 0.044, respectively). The overall incidence of C-KIT mutations was 33.3%, FLT3/internal tandem duplication (ITD) 6.6%, FLT3(D835) 10.0% and JAK2(V617F) mutations 3.3%. C… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…